|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||312.32 g/mol g·mol−1|
|3D model (JSmol)|
Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease.
Results of a phase II trial on insomnia in 120 adults were announced in 2013, finding piromelatine 20/50 mg improved sleep over 4 weeks vs placebo. Phase 1A/1B studies in 2011, showed safe dose-dependent improvement in sleep. Pre-clinical studies showed antinociceptive antihypertensive and cognitive benefits in rat disease models of pain, hypertension, and Alzheimer's disease.
- Liu, YY; Yin, D; Chen, L; Qu, WM; Chen, CR; Laudon, M; Cheng, NN; Urade, Y; Huang, ZL (October 2014). "Piromelatine exerts antinociceptive effect via melatonin, opioid, and 5HT1A receptors and hypnotic effect via melatonin receptors in a mouse model of neuropathic pain". Psychopharmacology. 231 (20): 3973–85. doi:10.1007/s00213-014-3530-5. PMID 24700387.
- Huang, L; Zhang, C; Hou, Y; Laudon, M; She, M; Yang, S; Ding, L; Wang, H; Wang, Z; He, P; Yin, W (September 2013). "Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats". European Review for Medical and Pharmacological Sciences. 17 (18): 2449–56. PMID 24089222.
- He, P; Ouyang, X; Zhou, S; Yin, W; Tang, C; Laudon, M; Tian, S (2013). "A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease". Hormones and Behavior. 64 (1): 1–7. doi:10.1016/j.yhbeh.2013.04.009. PMID 23651610.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|